Biogen: BeNeLuxA Spinraza Talks “Collaborative And Constructive" But Not Without Challenges
Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.
You may also be interested in...
Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks
The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.
Gene Therapy Libmeldy Undergoes Cross-Country HTA In Europe
Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.
European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.